EICHOR
● Not Yet Recruiting
SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer
Condition: NSCLC · Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
About this study
This is an open-label, multi-center, Phase II clinical study to evaluate the safety, tolerability, and efficacy of SKB264 in combination with SKB118 in participants with NSCLC. The study includes a dose escalation phase and an expansion phase.
This description comes directly from the study's public registry record.
Talk to the study team
Yan Qing Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · 028-67255480 · qingyan@kelun.com
Always discuss trial participation with your own doctor first.
Locations (2)
| Jilin Cancer Hospital | Jilin City, China | — |
| Shanghai East Hospital, Tongji University | Shanghai, China | — |
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07697586